We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
Supernus Pharmaceuticals (SUPN - Free Report) reported $153.76 million in revenue for the quarter ended March 2023, representing a year-over-year increase of 0.8%. EPS of $0.29 for the same period compares to $0.43 a year ago.
The reported revenue represents a surprise of +8.99% over the Zacks Consensus Estimate of $141.08 million. With the consensus EPS estimate being $0.12, the EPS surprise was +141.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Net product sales- Trokendi XR: $34.80 million versus the three-analyst average estimate of $25.74 million. The reported number represents a year-over-year change of -44.6%.
Revenues- Net product sales- Oxtellar XR: $28.90 million versus $28.36 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
Revenues- Royalty revenues: $13.20 million versus the three-analyst average estimate of $4.63 million. The reported number represents a year-over-year change of +161.8%.
Revenues- Net product sales- GOCOVRI: $26 million versus $28.75 million estimated by three analysts on average.
Revenues- Net product sales: $140.60 million versus the three-analyst average estimate of $136.40 million. The reported number represents a year-over-year change of -4.7%.
Revenues- Net product sales- Qelbree: $25.80 million versus the three-analyst average estimate of $27.59 million.
Shares of Supernus have returned -1.5% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Supernus Pharmaceuticals (SUPN - Free Report) reported $153.76 million in revenue for the quarter ended March 2023, representing a year-over-year increase of 0.8%. EPS of $0.29 for the same period compares to $0.43 a year ago.
The reported revenue represents a surprise of +8.99% over the Zacks Consensus Estimate of $141.08 million. With the consensus EPS estimate being $0.12, the EPS surprise was +141.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product sales- Trokendi XR: $34.80 million versus the three-analyst average estimate of $25.74 million. The reported number represents a year-over-year change of -44.6%.
- Revenues- Net product sales- Oxtellar XR: $28.90 million versus $28.36 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
- Revenues- Royalty revenues: $13.20 million versus the three-analyst average estimate of $4.63 million. The reported number represents a year-over-year change of +161.8%.
- Revenues- Net product sales- GOCOVRI: $26 million versus $28.75 million estimated by three analysts on average.
- Revenues- Net product sales: $140.60 million versus the three-analyst average estimate of $136.40 million. The reported number represents a year-over-year change of -4.7%.
- Revenues- Net product sales- Qelbree: $25.80 million versus the three-analyst average estimate of $27.59 million.
View all Key Company Metrics for Supernus here>>>Shares of Supernus have returned -1.5% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.